Silverarc Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Silverarc Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,036	Closed	-$645K	–	96
2022 Q2	$645K	Buy	+26,036	New	+$574K	0.2%	61
2021 Q2	–	Sell	-55,974	Closed	-$1.38M	–	125
2021 Q1	$2.87M	Buy	55,974 +2,208	+4%	+$133K	1.56%	25
2020 Q4	$3.33M	Buy	+53,766	New	+$3.08M	1.93%	19

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

SFM

Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Silverarc Capital Management's CCXI Position: Q3 2022 in Review

Silverarc Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 26,036 shares — an estimated $645K sold.

Silverarc Capital Management first reported a position in CCXI in Q4 2020 and held it in 3 quarters. The position peaked at $3.33M in Q4 2020. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

Silverarc Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
Silverarc Capital Management sold 26,036 ChemoCentryx, Inc. shares in Q3 2022, an estimated $645K.
Silverarc Capital Management first reported a position in ChemoCentryx, Inc. in Q4 2020 and held it in 3 quarters.
Silverarc Capital Management's ChemoCentryx, Inc. position peaked at $3.33M in Q4 2020.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.